The APhA Complete Review for Pharmacy (Gourley, APha Complete Review for Pharmacy)
- Buy New: $89.56
as of 12/9/2013 04:04 EST details
- Sales Rank:421,074
- Languages:English (Unknown), English (Original Language), English (Published)
- Number Of Items:1
- Shipping Weight (lbs):4
- Publication Date:January 15, 2012
Availability:Usually ships in 1-2 business days
The NAPLEX (North American Pharmacist Licensure Examination) is the standard licensing exam that all U.S. pharmacy students must pass to practice pharmacy. It's an arduous exam that tests a daunting range of knowledge. Approximately 10 per cent of students taking the exam for the first time fail to achieve a passing score. Preparing for the NAPLEX by reviewing all of the material from each pharmacy school course would be overwhelming. A far better approach would be to study only the information most relevant to the exam, summarized in abbreviated bullet format - and that's what The APhA Complete Review for Pharmacy contains. Features of this title include:
Top 200 drugs: Begin your NAPLEX preparation by learning the generic and trade names for the top 200 drugs,
Math: After generic and trade names, this is the most important single area to review,
Drug therapy for chronic and common diseases: This is the heart of today's NAPLEX and the subject of more than half of the 40 chapters in this study guide; and,
Summary tables of the major drug categories: Drug charts, including dosage schedules and dosage forms, are provided in each of the therapeutic chapters.
New to this edition are three new chapters - Drug Information, Biostatistics, and Clinical Trial Design.
An updated chapter on new drug approvals, indications, and formulations is also included.
This title includes review questions. All chapters end with 20 or more practice exam questions and answers as well as explanation that reinforce key learning points.
CERTAIN CONTENT THAT APPEARS ON THIS SITE COMES FROM AMAZON SERVICES LLC. THIS CONTENT IS PROVIDED ‘AS IS’ AND IS SUBJECT TO CHANGE OR REMOVAL AT ANY TIME.